Skip to main navigation

- Silverback - Corp Menu

About
Science & Technology
Pipeline
Careers
- Open Positions
Contact
Investors

News Releases

- Silverback - Investor Relations

Home
News & Events
Stock Information
- Stock Quote & Chart
Corporate Governance
Financials & Filings
- SEC Filings
IR Resources
- Email Alerts
- Contact IR

Year

Silverback Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

12-08-2020

Silverback Therapeutics Announces Pricing of Initial Public Offering

12-03-2020

Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting Digital Experience

11-13-2020

Silverback Therapeutics Expands Executive Team With Appointment of Healthcare Investment Banking Veteran Jonathan Piazza as Chief Financial Officer

11-10-2020

Silverback Therapeutics to Present Data on Two Programs at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting

11-09-2020

Silverback Therapeutics Raises $85 Million in Series C Financing; Company Announces Executive Promotions

09-23-2020

Silverback Therapeutics Initiates Phase 1 Clinical Study of SBT6050

08-26-2020

Silverback Therapeutics to Present Preclinical Data on SBT6050 Demonstrating Potent Activation of Human Myeloid Cells and the Potential for Single Agent Clinical Activity

06-22-2020

Silverback Therapeutics Appoints Vickie L. Capps to Board of Directors and Audit Committee Chair

06-04-2020

Silverback Therapeutics Announces Presentation of Preclinical Data at ASCO Supporting Potential Clinical Activity of SBT6050 as a Single Agent and in Combination with Trastuzumab for the Treatment of HER2-Expressing Malignancies

05-29-2020

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 15

- Silverback - Investor Tools

Print Page
RSS Feeds
Email Alerts

- Silverback - Corp Menu

About
Science & Technology
Pipeline
Careers
- Open Positions
Contact
Investors

© Copyright 2021 - Silverback Therapeutics^®